Oral adverse effects of CDK4/6 inhibitors among breast cancer patients: a systematic review and meta-analysis.

Long, Quanyi; Li, Xiaomin; Wu, Gonghua; Zhang, Jia; Li, Hongjiang

Long, Quanyi; Li, Xiaomin; Wu, Gonghua; Zhang, Jia; Li, Hongjiang.

Afiliação

Long Q; Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, China.
Li X; Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, China.
Wu G; Department of Biostatistics, School of Public Health, Sun Yat-Sen University, Guangzhou, China.
Zhang J; Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, China.
Li H; Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, China.

Ann Palliat Med ; 10(6): 6556-6563, 2021 Jun.

Article em En | MEDLINE | ID: mdl-34237967

Assuntos

Neoplasias da Mama; Neoplasias da Mama/tratamento farmacológico; Quinase 4 Dependente de Ciclina; Quinase 6 Dependente de Ciclina; Feminino; Humanos; Qualidade de Vida; Receptor ErbB-2

Palavras-chave

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6Is); breast cancer; palbociclib; stomatitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Qualitative_research / Systematic_reviews Aspecto: Patient_preference Limite: Female / Humans Idioma: En Revista: Ann Palliat Med Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google